World Health Organization , 2020. Global Tuberculosis Report 2020. Geneva, Switzerland: WHO. Available at: https://www.who.int/publications/i/item/9789240013131. Accessed March 3, 2021.
World Health Organization , 2014. The End TB Strategy. Geneva, Switzerland: WHO. Available at: http://www.who.int/tb/strategy/en/. Accessed March 9, 2020.
Cords O, Martinez L, Warren JL, O’Marr JM, Walter KS, Cohen T, Zheng J, Ko AI, Croda J, Andrews JR, 2021. Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis. Lancet Public Health 6: e300–e308.
Dara M et al.2015. Tuberculosis control in prisons: current situation and research gaps. Int J Infect Dis 32: 111–117.
Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F, 2010. Tuberculosis incidence in prisons: a systematic review. PLOS Med 7: e1000381.
Melchers NVSV, van Elsland SL, Lange JMA, Borgdorff MW, van den Hombergh J, 2013. State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control. PLOS ONE 8: e53644.
Mathema B, Andrews JR, Cohen T, Borgdorff MW, Behr M, Glynn JR, Rustomjee R, Silk BJ, Wood R, 2017. Drivers of tuberculosis transmission. J Infect Dis 216: S644–S653.
Dara M et al.2015. Tuberculosis control in prisons: current situation and research gaps. Int J Infect Dis 32: 111–117.
Rueda ZV, Arroyave L, Marin D, López L, Keynan Y, Giraldo MR, Pulido H, Arbeláez MP, 2014. High prevalence and risk factors associated with latent tuberculous infection in two Colombian prisons. Int J Tuberc Lung Dis 18: 1166–1171.
WHO-Europe , 2018. Good Practices in the Prevention and Care of Tuberculosis and Drug-Resistant Tuberculosis in Correctional Facilities. Available at: http://www.euro.who.int/__data/assets/pdf_file/0003/360543/TB-prisons-9789289052917-eng.PDF?ua=1. Accessed December 2, 2021.
Rueda ZV, López L, Vélez LA, Marín D, Giraldo MR, Pulido H, Orozco LC, Montes F, Arbeláez MP, 2013. High incidence of tuberculosis, low sensitivity of current diagnostic scheme and prolonged culture positivity in four Colombian prisons. A cohort study. PLoS One 8: e80592.
Arroyave L, Keynan Y, López L, Marin D, Arbeláez MP, Rueda ZV, 2017. Negative latent tuberculosis at time of incarceration: identifying a very high-risk group for infection. Epidemiol Infect 145: 2491–2499.
CDC , 2021. TB | Hojas Informativas-Pruebas de Tuberculosis. Available at: http://www.cdc.gov/tb/esp/publications/factsheets/testing/skintesting_es.htm. Accessed July 21, 2021.
Gizachew Beza M, Hunegnaw E, Tiruneh M, 2017. Prevalence and associated factors of tuberculosis in prisons settings of east Gojjam Zone, northwest Ethiopia. Int J Bacteriol 2017: 3826980.
Séri B et al.2017. Prevalence of pulmonary tuberculosis among prison inmates: a cross-sectional survey at the correctional and detention facility of Abidjan, Côte d’Ivoire. PLoS One 12: e0181995.
Winetsky DE, Almukhamedov O, Pulatov D, Vezhnina N, Dooronbekova A, Zhussupov B, 2014. Prevalence, risk factors and social context of active pulmonary tuberculosis among prison inmates in Tajikistan. PLoS One 9: e86046.
Fuge TG, Ayanto SY, 2016. Prevalence of smear positive pulmonary tuberculosis and associated risk factors among prisoners in Hadiya Zone prison, southern Ethiopia. BMC Res Notes 9: 201.
Navarro PD, Almeida IN, Kritski AL, Ceccato MD, Maciel MM, Carvalho WD, Miranda SS, 2016. Prevalence of latent Mycobacterium tuberculosis infection in prisoners. J Bras Pneumol 42: 348–355.
Aguilera XP et al.2016. Tuberculosis in prisoners and their contacts in Chile: estimating incidence and latent infection. Int J Tuberc Lung Dis 20: 63–70.
Urrego J, Ko AI, da Silva Santos Carbone A, Paião DSG, Sgarbi RVE, Yeckel CW, Andrews JR, Croda J, 2015. The impact of ventilation and early diagnosis on tuberculosis transmission in Brazilian prisons. Am J Trop Med Hyg 93: 739–746.
Paião DSLE, da Silva FMBL, Martins VSSS, Pompílio MA, Urrego J, Ko AI, Andrews JR, Croda J, 2016. Impact of mass-screening on tuberculosis incidence in a prospective cohort of Brazilian prisoners. BMC Infect Dis 16: 533.
Ferreira MM et al.1996. Tuberculosis and HIV infection among female inmates in São Paulo, Brazil: a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 13: 177–183.
Mamani M, Mahmudian H, Majzoobi MM, Poorolajal J, 2016. Prevalence and incidence rates of latent tuberculous infection in a large prison in Iran. Int J Tuberc Lung Dis 20: 1072–1077.
Weant TE, Turner AN, Murphy-Weiss M, Murray DM, Wang S-H, 2012. Can social history variables predict prison inmates’ risk for latent tuberculosis infection? Tuberc Res Treat 2012: 132406.
Kawatsu L, Uchimura K, Ohkado A, 2018. A situational analysis of latent tuberculosis infection among incarcerated population in Japan. PLoS One 13: e0203815.
del Corral H et al.2009. IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 4: e8257.
Guerra J, Mogollón D, González D, Sanchez R, Rueda ZV, Parra-López CA, Murcia MI, 2019. Active and latent tuberculosis among inmates in La Esperanza prison in Guaduas, Colombia. PLoS One 14: e0209895.
Nogueira PA, de Melo Abrahão RMC, Galesi VMN, 2012. Tuberculosis and latent tuberculosis in prison inmates. Rev Saude Publica 46: 119–127.
Al-Darraji HAA, Kamarulzaman A, Altice FL, 2014. Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health 14: 22.
Margolis B, Al-Darraji HAA, Wickersham JA, Kamarulzaman A, Altice FL, 2013. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. Int J Tuberc Lung Dis 17: 1538–1544.
He G et al.2015. The prevalence and incidence of latent tuberculosis infection and its associated factors among village doctors in China. PLoS One 10: e0124097.
Katelaris AL, Jackson C, Southern J, Gupta RK, Drobniewski F, Lalvani A, Lipman M, Mangtani P, Abubakar I, 2020. Effectiveness of BCG vaccination against Mycobacterium tuberculosis infection in adults: a cross-sectional analysis of a UK-based cohort. J Infect Dis 221: 146–155.
Chan P-C, Yang C-H, Chang L-Y, Wang K-F, Kuo Y-C, Lin C-J, Lee S-W, Hsueh P-R, Fang C-T, Huang L-M, 2013. Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax 68: 263–268.
Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P, 2016. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis 16: 219–226.
Marín D, Marín N, del Corral H, López L, Ramirez-Agudelo ME, Rojas CA, Arbeláez MP, García LF, Rojas M, 2017. PPD-induced monocyte mitochondrial damage is associated with a protective effect to develop tuberculosis in BCG vaccinated individuals: a cohort study. PLoS One 12: e0171930.
Roy A et al.2014. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 349: g4643.
Tekkel M, Rahu M, Loit HM, Baburin A, 2002. Risk factors for pulmonary tuberculosis in Estonia. Int J Tuberc Lung Dis 6: 887–894.
Campbell JR, Winters N, Menzies D, 2020. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ 368: m549.
Kalonji GM, De Connick G, Okenge Ngongo L, Kazumba Nsaka D, Kabengele T, Tshimungu Kandolo F, Ilunga-Ilunga F, Adelin A, Giet D, 2016. Prevalence of tuberculosis and associated risk factors in the central prison of Mbuji-Mayi, Democratic Republic of Congo. Trop Med Health 44: 30.
Noeske J, Ndi N, Mbondi S, 2011. Contrôle de la tuberculose dans les prisons face aux conditions de confi nement: une cause perdue? L’expérience du Cameroun. Int J Tuberc Lung Dis 15: 223–227.
Maceda EB, Gonçalves CCM, Andrews JR, Ko AI, Yeckel CW, Croda J, 2018. Serum vitamin D levels and risk of prevalent tuberculosis, incident tuberculosis and tuberculin skin test conversion among prisoners. Sci Rep 8: 997.
Morasert T, Worapas W, Kaewmahit R, Uphala W, 2018. Prevalence and risk factors associated with tuberculosis disease in Suratthani Central Prison, Thailand. Int J Tuberc Lung Dis 22: 1203–1209.
Massoglia M, Pridemore WA, 2015. Incarceration and health. Annu Rev Sociol 41: 291–310.
Whitaker JA, Mirtskhulava V, Kipiani M, Harris DA, Tabagari N, Kempker RR, Blumberg HM, 2013. Prevalence and incidence of latent tuberculosis infection in Georgian healthcare workers. PLoS One 8: e58202.
Ossa H et al.2016. Outlining the ancestry landscape of Colombian admixed populations. PLoS One 11: e0164414.
Bick JA, 2007. Infection control in jails and prisons. Clin Infect Dis 45: 1047–1055.
Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR, 2018. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev 31: e00021–e18.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1083 | 427 | 19 |
Full Text Views | 120 | 84 | 8 |
PDF Downloads | 123 | 81 | 6 |
People deprived of liberty (PDL) are at high risk of acquiring Mycobacterium tuberculosis infection (latent tuberculosis infection [LTBI]) and progressing to active tuberculosis (TB). We sought to determine the incidence rates and factors associated with LTBI and active TB in Colombian prisons. Using information of four cohort studies, we included 240 PDL with two-step tuberculin skin test (TST) negative and followed them to evaluate TST conversion, as well as, 2,134 PDL that were investigated to rule out active TB (1,305 among people with lower respiratory symptoms of any duration, and 829 among people without respiratory symptoms and screened for LTBI). Latent tuberculosis infection incidence rate was 2,402.88 cases per 100,000 person-months (95% CI 1,364.62–4,231.10) in PDL with short incarceration at baseline, and 419.66 cases per 100,000 person-months (95% CI 225.80–779.95) in individuals with long incarceration at baseline (who were enrolled for the follow after at least 1 year of incarceration). The TB incidence rate among PDL with lower respiratory symptoms was 146.53 cases/100,000 person-months, and among PDL without respiratory symptoms screened for LTBI the incidence rate was 19.49 cases/100,000 person-months. History of Bacillus Calmette-Guerin vaccination decreased the risk of acquiring LTBI among PDL who were recently incarcerated. Female sex, smoked drugs, and current cigarette smoking were associated with an increased risk of developing active TB. This study shows that PDL have high risk for LTBI and active TB. It is important to perform LTBI testing at admission to prison, as well as regular follow-up to control TB in prisons.
Authors’ addresses: Mariana Herrera, María Patricia Arbeláez, and Lázaro Vélez, Universidad de Antioquia, Medellin, Antioquia, Colombia, E-mails: marianah8@hotmail.com, mariapatriciaa@gmail.com, and clamona@une.net.co. Yoav Keynan, Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba, Winnipeg, Manitoba, Canada, E-mail: yoav.keynan@umanitoba.ca. Lucelly López and Diana Marín, Universidad Pontificia Bolivariana, Medellin, Colombia, E-mails: lucelly.lopez@upb.edu.co and dianamarcela.marin@upb.edu.co. Luisa Arroyave, Universidade Federal de Pelotas, Pelotas, RS, Brazil, E-mail: arroyave.lf@gmail.com. Zulma Vanessa Rueda, Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba, Winnipeg, Manitoba, Canada, and Universidad Pontificia Bolivariana, Medellin, Colombia, E-mail: zulmaruedav@gmail.com.